

evidence for decicisons

101 introduction to reimbursement / funding for e-health and diagnostic companies

Why the obvious is not so obvious!?

CLICK HERE TO SEE THE FULL WEBINAR

CONFIDENTIAL AND PROPRIETARY Any use of this material without specific permission of Synergus RWE AB is strictly prohibited

1	Synergus RWE			
2	Introduction			
3	Funding and Reimbursement			
4	Health care systems			
5	Decicsion making			
6	Conclusion			


Core services

Securing Market Access	Evidence For Decisions	
 Reimbursement analysis and strategy Procedure coding DRG Evidence requirements HTA Analysis Market access pathway Hands-on execution and engagement with stakeholders Application for reimbursement and coding 	 Real World Evidence European strategy Leveraging both national as well as disease specific data sets. Execution of RWE studies HEOR Health Economic modelling Systematic literature reviews Sales tools (Ipad) 	
Device DX E- health	Device DX E- health Drugs	

STRATEGIC UNDERSTANDING AND PLANNING TO OPTIMIZE EVERY STEP IN THE PROCESS



Evidence For Decisions



Securing Market Access

Analytical

Europe

- Austria
- Belgium
- Denmark
- Finland
- France
- Germany
- Italy
- Netherlands
- Norway
- Poland
- Spain
- Sweden
- Switzerland
- The United Kingdom



Middle East

- Egypt
- Lebanon,
- Saudi Arabia
- United Arab Emirates

Hands on

Europe

- Belgium,
- Denmark
- France
- Germany
- Netherlands
- Norway
- Sweden
- Switzerland
- The United Kingdom



Evidence For Decisions

RWE analysis **RWE Strategy and HE modelling** Europe Europe Finland Austria • • France Belgium • ٠ Denmark Germany • ٠ Finland Netherlands • . Norway France • • Spain • Germany • ζ रे Sweden Italy ٠ • Netherlands The United • • Norway Kingdom • ď Poland ٠ ď Spain • • Sweden Switzerland • • The United Kingdom

1	Synergus RWE			
2	Introduction			
	2.1	Terminology		
	2.2	Economic reality		
	2.3	Your customer determines the sales perspective		
3	Funding and Reimbursement			
4	Health care systems			
5	Decicsion making			
6	Conclusion			

Webinar introduction

- Target audience:
 - E-health companies with limited experience / understanding in market access from drugs and devices.
 - Market access professionals with experience in drugs or devices, but limited experience in ehealth / diagnostics.
- Objective:
 - Understanding of the complex reality of market access for e-health and diagnostics
 - Foundation to understand consequent webinars:
 - Provide basic introduction to concepts that are essential to understand
 - Sign up for the webinar February 21st : HTA evaluation of e-health solutions
 - Provide guidance on where to focus your effort

E-health has the ability to transform healthcare




The Next Logical Ste Precision Oncology

Water-bases that 1 th characteristic Stiger can be first avail for good for its privates. One means to of management are filling. And it with the DOD is sense in the structure destination.

1800+

2000



* https://www.cbinsights.com/research/apple-healthcare-strategy-apps/

22 000+

8500+

1	Synergus RWE			
2	Introduction			
	2.1	Terminology		
	2.2	Economic reality		
	2.3	Your customer determines the sales perspective		
3	Funding and Reimbursement			
4	Health care systems			
5	Decicsion making			
6	Conclusion			

Existing payment mechanisms in health care

Doctors visit





Device




Drug




Elderly care

Diagnostics (?)








Where does e-health belong?




Different type of diagnostics will raise different type of market access questions




Only a couple of countries in Europe has methods in place how to evaluate the value of IVD's connected to a reimbursement decision !?


Defining e-health crucial to understand the market access challenge



E-health and comparison to traditional funding / reimbursement scenarios




What are the major themes in the e-health solutions (therapeutic / diagnostic) ?



1	Synergus RWE		
2	Introduction		
	2.1 Terminology		
	2.2	Economic reality	
	2.3	Your customer determines the sales perspective	
3	Funding and Reimbursement		
4	Health care systems		
5	Decicsion making		
6	Conclusion		

Development of health care spending 2005-2015




The increased cost of health care across Europe has a significant impact on the introduction of new innovations.

> 2% 1% - 2% < 1%

Annual increase in GDP expenditure on health care:


Country	Health care spending of GDP (2015)
Switzerland	11.5%
Germany	11.1%
Sweden	11.1%
France	11.0%
Netherlands	10.8%
Denmark	10.6%
Austria	10.4%
Belgium	10.1%
Norway	9.9%
United Kingdom	9.8%
Finland	9.6%
Italy	9.1%
Spain	9.0%
Poland	6.3%

How do we interpret the increasing spending in health care?



1	Syne	Synergus RWE		
2	Intro	Introduction		
	2.1	Terminology		
	2.2	Economic reality		
	2.3	Your customer determines the sales perspective		
3	Funding and Reimbursement			
4	Health care systems			
5	Decicsion making			
6	Conclusion			

Therapy Development & Reimbursement A multi-disciplinary approach



1	Synergus RWE				
2	Introduction				
3	Funding and Reimbursement				
4	Health care systems				
5	Decicsion making				
6	Conclusion				

Reimbursement vs funding

Reimbursement

- The mechanism to pay for intervention
- The most common mechanisms include diagnosis-related groups (DRGs), fee for service, and global budget
- Reimbursement represents "mechanics" of payment, which often might be artificial, especially for novel procedures with no established specific reimbursement
- In most countries there is no correlation between the existence of a reimbursement mechanism and the willingness to pay for the intervention
- Countries differ in requirements for changes in the reimbursement system. Some don't have any evidence requirements, some have very high requirements

Funding / Commissioning

- The way to define which interventions are covered and which are not; willingness to pay for procedure
- In most countries the decision to fund or commission the extent of use of an intervention is not clearly defined
- In most countries multiple stakeholders are involved in funding decisions, including the ministry of health or other defined commissioners and health technology assessment bodies
- The common theme among these organizations is the informed decision based on evidence and economical implications

Reimbursement and funding represent two different challenges

Examples

• A medical aid has a tariff/reimbursement defined for use.



- Payer / commissioner do not see the value of using the medical aid and consequently do not fund the use of the technology.
 - The reimbursement does not matter. It is only a price tag.

- There are budgets available at both national and at hospitals to fund for the use of solutions which do not fit in the standard ways.
 - Typically limited in time and limited budget available.
 - Can be very valuable as a starting point, but be aware of the limitations.
- If a solution is able to demonstrate a costsaving within the budget of the potential buyer, there is no need to worry about funding or reimbursement. This is obviously the best scenario.

It is crucial to understand the short and long term solution for reimbursement and funding /commissioning as this may be the most critical parameter for the success.

1	Synergus RWE		
2	Introduction		
3	Funding and Reimbursement		
	Health care systems		
4	Health care systems		
4 5	Health care systems Decicsion making		

Financing of healthcare systems

There are three types of healthcare systems and in general two are used in Europe with each country still having their own particularities.

The Beveridge 'public' model


- Funding is based mainly on taxation characterized by a centrally organized National Health Service services are provided mainly by public health providers e.g. hospitals, community doctors.
- Healthcare budgets compete with other spending priorities.

The Bismarck 'mixed' model

- Funded mainly by a premium-financed social / mandatory insurance
- This model results in a mix of private and public providers, and allows more flexible spending on healthcare

The 'private' insurance model

- Funding of the system is based on **premiums, paid** into private insurance companies
- In this system, the **funding is** predominantly **private**, with the exception of social care
- The great majority of the **providers** in this model belong to the **private sector**.



How are health interventions reimbursed? How is it possible to change the system?

Centralized - Strict reimbursement/HTA barrier for introduction of new devices / procedures

- A centralized decision-making process that includes HTA when establishing the reimbursement of a new procedure/device.
- High level of clinical evidence is required and economic evidence might be required
- Alignment of Key Opinion Leaders and payers is important
- Device/procedure can't be used prior to obtaining permission

Centralized - Reimbursement barrier for the introduction of new devices/procedures


- A centralized decision-making process that includes HTA when establishing the reimbursement of a new procedure/device.
- High level of clinical evidence is required and economic evidence might be required
- Alignment of Key Opinion Leaders and payers is important
- Device/procedure <u>can be used to limited extend prior to obtaining</u>
 <u>permission</u>

Centralized - Gradual change of DRG system

- Changes are introduced via the DRG system
- No evidence requirements from the DRG system
- Economic evidence is usually not required
- Adoption by clinicians is a key to create an inclusion

Decentralized - Decision about introduction of new procedure/device is made locally

- Clinicians are key players
- Hospital administration influences the adoption of technology
- Hospital-based HTA can be common



Different reasons in different countries for decision making.




Figure 3. Rationale for positive and negative recommendations

1	Synergus RWE				
2	Intro	Introduction			
3	Funding and Reimbursement				
4	Health care systems				
5	Decicsion making				
	5.1	DRG s	system		
	5.2	HTA e	A evaluation		
5.3 Comparative Efectivness - Health Economics		arative Efectivness - Health Economics			
		5.3.1	Quality of Life		
		5.3.2	Target indication		
6	Conclusion				

Ways to make decision about funding / reimbursement

Doctors visit





Device



Medical aid

Drug



Elderly care

Diagnostics (?)






Payment is linked to required resources / cost

Changes are based on disconnect in payment and required resources

DRG system is key-concept






1	Synergus RWE			
2	Introduction			
3	Funding and Reimbursement			
4	Health care systems			
5	Decicsion making			
	5.1	DRG s	system	
	5.2	HTA e	A evaluation	
5.3 Comparative Efectivness - Health Economics		arative Efectivness - Health Economics		
		5.3.1	Quality of Life	
		5.3.2	Target indication	
6	Conclusion			

How does DRG relate to e-health?

- Some e-health solutions will be in a setting where they preferably would be placed in a DRG reimbursement.
- It is important to have a high-level understanding of this method in order to understand why it is not applicable.

Payment mechanisms in healthcare services

- Global budget
 - Fixed budget for providers
 - Possible slow adjustments to changes in volumes/costs
- Fee-for-service (FFS)
 - Retrospective reimbursement
 - Each service reimbursed with a fee reflecting costs/efforts/specialization required
 - May encouraged excessive services and unnecessary / inappropriate care
- Pay-for-performance (P4P)
 - Attempt to link payment to quality
- Diagnosis-related group system (DRG system)
 - Linking of reimbursement to the expected extent of care required by single cases/admissions
 - Overtreatment, readmissions



Health care provider can use the money as they wish. No formal process to be included. Good opportunity if the budget is available ..


DRG – A system to distribute healthcare funds




The core function of a DRG system does not have **any evaluation of the 'value'** of the procedures being provided. It is intended to provide a fair model to distribute money.

Components of DRG System






Diagnosis Related Groups




What is included in the DRG tariff




DRG's include the average cost for all expenses from a patient from admission to discharge.

DRG tariffs are not intended to cover the cost of each individual procedure but should suffice on average



Sufficient volume and cost discrepancy make a DRG change necessary A change of coding is required to distinguish different interventions



Agenda

1	Synergus RWE		
2	Introduction		
3	Funding and Reimbursement		
4	Health care systems		
5	Decicsion making		
	5.1 DRG system		
	5.2 HTA evaluation		
	5.3 Comparative Efectivness - Health Economics		
		5.3.1	Quality of Life
		5.3.2	Target indication
6	Conclusion		

Making decisions what to buy and how to determine the value of different alternatives?

Which fruit should I buy?



How many should I buy / can I afford?

How should I compare the value / determine the price?







The evaluation framework



Health Technology Assessment (HTA)






How does the use of the new solution impact cost and outcomes compared to current treatment over a longer period of time.








Status of established evaluation frameworks connected to reimbursement




HTA – In EU Decision Making Model



Ref. Health Technology Assessment and Health Policy-Making in Europe, Marcial Velasco Garrido, Observatory studies Series no. 14, European Observatory for health policy publication, ISBN 978 92 890 4293 2

What Health Technololgy Assesment organisations (HTA) Look for?



Hierarchy of Evidence



In most HTA frameworks there is no or limited recognition of the value of Real World Evidence. This may however be a significant opportunity for e-health solutions.

Differences in HTA processes around Europe (Medical devices)



Formal HTA process Clear link to reimbursement Impact on diffusion



Formal HTA process No clear link to reimbursement Impact on diffusion

Regional HTA Impact on regional/local settings

Very sporadic or no HTA


Key messages

- Only in several European countries health technology assessment is connected to reimbursement system
- In majority health technology assessment carries only advisory role

** All innovative products may require national or mini-HTA

^{*} Very sporadic in-patient, formal HTA process with clear link to reimbursement and diffusion in out-patient sector. In process to implement HTA for assessment of innovations in hospital settings.

Hospital/mini-health technology assessment use in Europe



Agenda


1	Synergus RWE			
2	Introduction			
3	Funding and Reimbursement			
4	Health care systems			
5	Decicsion making			
	5.1	DRG s	system	
	5.2 HTA evaluation			
	5.3 Comparative Efectivness - Health Economics			
		5.3.1	Quality of Life	
		5.3.2	Target indication	
6	Conclusion			

Comparative effectiveness – The foundation for assessments

"The comparative analysis of alternative courses of action in terms of both their costs and consequences in order to assist policy decisions" (Drummond et al)


Always comparative analysis

Comparison of both costs and Consequences




ICER should be below the Willingness-To-Pay of each payer (e.g. in UK it is 30,000 £ / QALY) *Assuming B as a new intervention having more costs and effects

Basic concept of economic evaluation




- Economic analysis includes comparative analysis of clinical and economic consequences of two treatment methods
- Results of cost-effectiveness analysis are presented in the form of increment cost-effectiveness ratio. It shows how much extra society shall pay for one additional year of health (quality-adjusted)

Reimbursement Potential: Which Quadrant?



WTP = Willingness To Pay or Cost Effectiveness Threshold (e.g. In UK £25 000 - £35 000)

Different types of economic models




(if recommended by the authority)

Agenda

1	Synergus RWE			
2	Introduction			
3	Funding and Reimbursement			
4	Health care systems			
5	Decicsion making			
	5.1	DRG s	system	
	5.2 HTA evaluation			
	5.3 Comparative Efectivness - Health Economics			
		5.3.1	Quality of Life	
		5.3.2	Target indication	
6	Conclusion			

Quality of Life



health state

Quality of Life Value : Methods of Elicitation*

■Generic QoL ■Disease Specific QoL	 Preference-based QoL Non preference-based QoL 	Combination • Generic preference based • Disease specific preference based	
Generic Questions	Disease specific questions	Preference based questions	
 How are you today? Do you have any problem to work? Do you have any problem to sleep? 	 Did you feel pain in your ankle joint in the last 12 hours? How severe was the Pain if you rank it on a scale of 1-5 where 5 is worst? 	 Which life you prefer between – 1. Additional 20 years of life with 50% mobility – or 2. Additional 14 years of life with 100% mobility? 	

In Europe the preference-based method is recommended by most of the evaluation authorities

*Simplified example

Quality of Life Measurement

The best suited for detecting small changes in disease-related quality of Diseaselife. Acknowledged by clinical community. Can't be directly used in economic evaluations. Additional studies are required. Example: Kansas specific City Cardiomyopathy Questionnaire for heart failure area Multi-dimensional health profile provides information about different aspects of life, such as mobility, pain, cognitive functioning etc. Health Health profile profile data may allow comparison with other diseases and treatments. Example: SF-36. SF-36 may be used in economic evaluations Patients preferences for the condition is collected. Example: EQ-5D, SF-6D, Preference Health Utility Index. Generic measures are the preferred tools for economic measures evaluations

Indirect Measurement of Preferences – EQ-5D

By placing a tick in one box in each group below, please indicate which statements best describe your own health state today

Mobility

I have no problems in walking about I have some problems in walking about I am confined to bed

Self-Care

I have no problems with self-care I have some problems washing or dressing myself I am unable to wash or dress myself

Usual Activities (e.g. work, study, housework, family or leisure activities)

I have no problems with performing my usual activities I have some problems with performing my usual activities I am unable to perform my usual activities



Pain/Discomfort

I have no pain or discomfort I have moderate pain or discomfort I have extreme pain or discomfort

Anxiety/Depression

I am not anxious or depressed I am moderately anxious or depressed I am extremely anxious or depressed

Source: adapted from the EuroQol Group: www.euroqol.org

- EQ-5D is the method of choice in most CUAs
- Simple and well suited questionnaire for self-completion by participants
- EQ-5D is the preferred HRQoL meassurement for NICE
- EQ-5D-5L version is available which allows greater sensitivity

Agenda


1	Synergus RWE			
2	Introduction			
3	Funding and Reimbursement			
4	Health care systems			
5	Decicsion making			
	5.1	DRG s	system	
	5.2 HTA evaluation			
	5.3 Comparative Efectivness - Health Economics			
		5.3.1	Quality of Life	
		5.3.2	Target indication	
6	Conclusion			

Balancing financial impact is critical for decision-makers in the case of expensive innovations




It is critical to inform decision-makers about budget impact and it is better to have a modest and even innocent proposition

Changing mindset: moving from regulatory to reimbursement perspective




Several questions for discussion



- When device may be more valuable in specific population?
- How to identify patient sub-groups with the highest unmet need?
- How to adjust clinical and market access strategy?
 - Clinical research
 - Economic evaluations


What is your target indication



Agenda

1	Synergus RWE
2	Introduction
3	Funding and Reimbursement
4	Health care systems
5	Decicsion making
6	Conclusion

Replacing the term e-health (therapeutic / diagnostic..) with Disease Management Tools?



- The assessment of the e-health solutions will be based on the impact it has on the disease in terms of:
 - Cost for health care
 - Clinical outcomes
 - Patient related outcomes
- It will be assessed as a tool to improve the management of the disease.
- Using the term Disease Management Tools helps to create clarity of how this is different then administrative solutions in e-health and also help you as a company to have the right perspective of what you are trying to accomplish.
- Disease Management Tool

Conclusion

Many ways to find money	 There are many ways to find the money for the use o your solution. Try the easy ways first. 		
Limitations in reimbursement systems may 'kill' your plan!	 There are many (stupid) limitations in current reimbursement systems that may prevent your commercial plan. Be aware! 		
Know the long term strategy	 Make sure you understand the long-term strategy to establish reimbursement. Many of the processes takes a long time. 		
Understand your target indication	 Understand what the comparative treatment is for your solution and for which patients your solution can provide relevant value. 		
Develop clinical and economical evidence	 Decision makers will require evidence to make decision. Make sure to develop both clinical and economical evidence for the value for your therapy. 		

Coming webinars

Торіс	Date	Speaker
• Funding and reimbursement of E-health in France	31 Jan	Michel Verhasselt
HTA evaluation of e-health solutions	21 Feb	Dr Kristian Kidholm
• Funding and reimbursement of E-health in Germany	28 Feb	Dr Thomas Seeger
 Developing an RWE strategy. Part 1: Defining the variables and outcomes of interest 	07 Mar	Mattias Kyhlstedt
• Funding and reimbursement of E-health in The Netherlands	28 Mar	Wim Meijer

Thank you for listening!

Let us know if we can be of any support.

Contact for questions: mattias.kyhlstedt@synergusrwe.com

CLICK HERE TO SEE THE FULL WEBINAR